Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 43204 gel in actinic keratosis on scalp
2014-000037-23Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- May 2014
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ingenol disoxate in actinic keratosis (AK), sponsored by LEO Pharma. Primary endpoints: Dose limiting toxicity (DLT) up to and including Day 8 (Part 1) and Safety of escalating doses (Part 1). Started May 2014; status: completed.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2014-000037-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000037-23.